Karyopharm Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (28)

Latest Posts

About This Stock More About This Stock
JPMorgan Upgrades Karyopharm After Doctor Survey, Doubles Price Target
Article By: The Fly
Tuesday, July 23, 2019 9:17 AM EST
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8.
In this article: KPTI
Read
Wedbush Boosts Karyopharm Target To $11 From $6 On Xpovio Approval
Article By: The Fly
Friday, July 5, 2019 9:50 AM EST
Wedbush analyst David Nierengarten raised his price target for Karyopharm Therapeutics to $11 from $6 after the FDA on Wednesday approved selinexor, now branded as Xpovio.
In this article: KPTI
Read
Karyopharm Drops 40% After FDA Posts Selinexor Meeting Briefing Docs
Article By: The Fly
Friday, February 22, 2019 2:49 PM EST
Shares of Karyopharm are moving sharply lower after the FDA posted briefing documents for the Oncologic Drugs Advisory Committee Meeting planned for February 26 to review the New Drug Application for Selinexor.
In this article: KPTI
Read
Stocks For You To Swing-Trade: KPTI, SPR, LNG
Article By: Ryan Mallory
Friday, July 20, 2018 5:56 AM EST
Take a look at three trading ideas to prep you for the next trading session.
In this article: SPR, LNG, KPTI
Read
Week In Review: Grail, An Oncology Diagnostics Company, Taps China Investors For $300 Million
Article By: ChinaBio® Today
Saturday, May 26, 2018 4:42 PM EST
Grail, a Hong Kong-US oncology diagnostics company, announced a $300 million C financing. The company is sequencing large populations of people -- some with cancer, some without -- to discover an early blood-based diagnostic test for cancer.
In this article: ILMN, KPTI
Read

PARTNER HEADLINES

Latest Tweets for $KPTI

No tweets yet!